The Committee for Medicinal Products for Human Use, CHMP, adopted a positive opinion recommending a variation to the terms of the marketing authorization for the medicinal product Prevenar 13, held by Pfizer. The CHMP adopted a change to an indication as follows: ¡°Active immunisation for the prevention of invasive disease caused by Streptococcus pneumoniae in adults ¡Ý18 years of age and the elderly.¡±
The Dow Jones fell as Elon Musk made a Tesla move. The Donald Trump stock sank on the stock market today. Cathie Wood bought a diving stock.
Bill Gates, the eighth richest person in the world, has a well-documented affinity for dividend income. This investment preference is clearly reflected in the staggering $463.2 million his portfolio is expected to pay him this year. Gates's investment strategy, rooted in picking companies with strong dividend yields, showcases his commitment to steady, long-term income streams. The Bill & Melinda Gates Foundation Trust’s most recent 13F filing reveals that a significant portion of this income is
Investors rarely get a chance to buy growth stocks at such depressed valuations.
I am a dividend investor, and I prize dividend consistency. I just can't trust what this high-yield income stock says about its dividend.
David Tepper is one of the best-performing hedge fund managers.
You can invest along with Carl Icahn with this stock.
California fast-food employees started earning a minimum of $20 an hour in April. Thanks to a new law, which went into effect earlier this month, California chain restaurants with at least 60 locations nationwide have to pay their employees more. For smaller restaurants, the minimum wage continues to be the statewide bottom of $16 an hour. The largest publicly-traded fast-food companies include McDonald’s Corp (NYSE:MCD); Starbucks Corp (NASDAQ:SBUX); Yum! Brands, Inc. (NYSE:YUM), which owns Tac
President Joe Biden has spent $23 billion of the $39 billion he has to spur chipmaking in the US, spreading it to companies that plan new activities in several states.
The popular growth-stock investor is hoping to get back on track in 2024. She's making moves this week.
Intra-Cellular Therapies stock rocketed Tuesday after its drug, Caplyta, topped expectations in a depression treatment study.
